Analytical data in connection with the clinical use of di-n-propylacetate
conference paper
Serum levels of dipropylacetate (DPA) (based on median scores to avoid sample spread as much as possible) have been collected from laboratory records. The only criterion for selection was a minimum number of three measurepoints per patient. In this way 167 median levels concerning the patients involved (82 males, 85 females; 114 in-patients, 53 out-patients) were estimated. These levels were plotted (Table 1) in relation to body weights for doses of 900 mg/24 hrs, 1,200 mg/24 hrs and 1,800 mg/24 hrs by least square analysis showing exponential regression (so-called logistic curves). These scores were henceforth used as “expected” or “normal” values. The 1,500 mg/24 hrs series in the table were not plotted by least square analysis because of lack of data in the lower weight classes. These figures were calculated by estimating class-means and extra-polation. Data concerning the 1,500 mg/hrs regimen were omitted.
TNO Identifier
287253
ISBN
978-3-642-85923-6
Publisher
Springer
Source title
Clinical Pharmacology of Anti-Epileptic Drugs: Workshop on the Determination of Anti-Epileptic Drugs in Body Fluid II (WODADIBOF II) Held in Bethel, Bielefeld, Germany, 24 - 25 May, 1974
Editor(s)
Schneider, H.
Janz, D.
Gardner-Thorpe, C.
Meinardi, H.
Sherwin, A.L.
Janz, D.
Gardner-Thorpe, C.
Meinardi, H.
Sherwin, A.L.
Place of publication
Heidelberg
Pages
235-241
Files
To receive the publication files, please send an e-mail request to TNO Repository.